Efficacy and Safety of Peripherally Acting μ-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review.
opioid induced constipation
opioid-induced bowel dysfunction
opioids
pain
pamora
peripherally acting m-opioid receptor antagonist
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
14
06
2021
accepted:
05
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
In treating chronic and acute pain, opioids are widely used. Although they do provide analgesia, their usage does come with adverse events (AEs). One of the most burdensome is opioid-induced bowel dysfunction, and more specifically opioid-induced constipation (OIC). The pathogenesis of these AEs is well known as the consequence of the action of opioids on m-receptors in the enteric nervous system. In recent years, medicines counteracting this specific action at the receptors have been registered for clinical use: the peripherally acting μ-opioid receptor antagonists (PAMORAs). The knowledge of their comparative efficacy and tolerability is very important for physicians and patients in opioid therapy. This systematic review of the existing literature on PAMORAs aimed to study the relative clinical advantages and disadvantages. The most important data banks, including "PubMed," "Embase," "CT.gov," "ICTRP" and "CINAHL" were used to find the published material on PAMORAs. The selected publications were examined to systematically analyze the efficacy and safety of the four existing PAMORAs. All of the medications are superior to placebo in reducing OIC. There are few published data on alvimopan used to treat OIC, and it is only indicated for the treatment of post-abdominal surgery ileus. Methylnaltrexone is studied mainly in its subcutaneous (SC) formulation. When used in its oral formulation, it seems more rapid than naloxegol and placebo in the reduction of OIC. Naldemedine is able to produce more spontaneous bowel movements (SBMs) when compared to alvimopan and naloxegol. Tolerability was found to be similar for all of them. In particular, they affect the gastrointestinal tract (GI), with flatulence and diarrhea, especially at high dosages. For some of them, nasopharyngitis and abdominal pain were observed as treatment adverse effects (TEAs). Several cardiovascular TEAs were reported after methylnaltrexone use, but it is not clear whether they were consequences of the drug or related to the general conditions of the patients. Considering the existing data, naloxegol and naldemedine seem to be the best choices, with a higher number of spontaneous bowel movements following naldemedine administration.
Identifiants
pubmed: 34367804
doi: 10.7759/cureus.16201
pmc: PMC8339109
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e16201Informations de copyright
Copyright © 2021, Rekatsina et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):555-564
pubmed: 28576452
J Clin Oncol. 2017 Dec 1;35(34):3859-3866
pubmed: 28968171
Clin Pharmacol Drug Dev. 2020 Feb;9(2):162-174
pubmed: 30977959
United European Gastroenterol J. 2019 Feb;7(1):7-20
pubmed: 30788113
Pain. 2013 Sep;154(9):1542-1550
pubmed: 23726675
Korean J Pain. 2019 Apr 1;32(2):69-78
pubmed: 31091505
Curr Med Res Opin. 2005 Oct;21(10):1555-68
pubmed: 16238895
Int Urol Nephrol. 2021 Jan;53(1):77-82
pubmed: 32869174
Pain Ther. 2020 Dec;9(2):657-667
pubmed: 32940898
J Opioid Manag. 2009 May-Jun;5(3):137-44
pubmed: 19662923
Am J Hosp Palliat Care. 2006 Jun-Jul;23(3):229-35
pubmed: 17060284
Scand J Pain. 2016 Apr;11:111-122
pubmed: 28850449
J Pain. 2011 May;12(5):554-62
pubmed: 21429809
Int J Clin Pract. 2015 Dec;69(12):1448-56
pubmed: 26344578
Aliment Pharmacol Ther. 2014 Oct;40(7):771-9
pubmed: 25112584
Pain Ther. 2021 Jun 3;:
pubmed: 34081260
Curr Gastroenterol Rep. 2013 Sep;15(9):344
pubmed: 23900996
N Engl J Med. 2008 May 29;358(22):2332-43
pubmed: 18509120
J Pain Symptom Manage. 2010 Jul;40(1):e1-3
pubmed: 20619194
Dis Colon Rectum. 2012 May;55(5):611-20
pubmed: 22513441
J Pain Res. 2020 Mar 24;13:605-612
pubmed: 32280263
J Palliat Med. 2015 Jul;18(7):593-600
pubmed: 25973526
J Pain Palliat Care Pharmacother. 2009;23(3):231-41
pubmed: 19670020
ESMO Open. 2019 Jul 31;4(4):e000527
pubmed: 31423335
Drugs Aging. 2020 Apr;37(4):271-279
pubmed: 32086791
J Pain Res. 2018 Oct 23;11:2509-2516
pubmed: 30425563
Expert Rev Gastroenterol Hepatol. 2020 Jan;14(1):39-46
pubmed: 31893959
JAMA. 2000 Jan 19;283(3):367-72
pubmed: 10647800
Aliment Pharmacol Ther. 2007 Jan 1;25(1):47-57
pubmed: 17042776
Pain Med. 2017 Oct 1;18(10):1837-1863
pubmed: 28034973
J Pain Symptom Manage. 2002 Jan;23(1):48-53
pubmed: 11779668
J Pain Palliat Care Pharmacother. 2011;25(2):136-45
pubmed: 21657861
J Pain Res. 2018 Dec 24;12:127-138
pubmed: 30613161
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1569-1584.e2
pubmed: 29374616
Postgrad Med. 2016;128(3):282-9
pubmed: 26839023
J Pediatr Orthop. 2021 May 18;:
pubmed: 34001807
J Pain. 2011 Feb;12(2):185-93
pubmed: 21292169
J Pain Symptom Manage. 2009 Nov;38(5):683-90
pubmed: 19713070
Am J Gastroenterol Suppl. 2014 Sep 10;2(1):17-21
pubmed: 25207608
Pain Med. 2017 Dec 1;18(12):2350-2360
pubmed: 28371937
Drugs. 2015 Mar;75(4):419-25
pubmed: 25666542
Drug Alcohol Depend. 2009 Nov 1;105(1-2):154-9
pubmed: 19647958
J Pharmacol Exp Ther. 2002 Jan;300(1):118-23
pubmed: 11752106
A A Pract. 2019 Jan 15;12(2):44-46
pubmed: 30020107
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):203-212
pubmed: 29870734
Value Health. 2011 Jan;14(1):177-83
pubmed: 21211500
United European Gastroenterol J. 2015 Oct;3(5):471-80
pubmed: 26535126
Clin Ther. 2017 Jan;39(1):75-88
pubmed: 27938897
Eur J Pharm Sci. 2018 May 30;117:187-192
pubmed: 29432808
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Pain Med. 2017 Aug 1;18(8):1496-1504
pubmed: 28810695
Int J Urol. 2021 Jun;28(6):696-701
pubmed: 33769634
J Pain Res. 2018 Dec 24;12:139-150
pubmed: 30613162
Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:3-16
pubmed: 15357847
Pain Pract. 2015 Jul;15(6):564-71
pubmed: 24815199
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
J Pain Symptom Manage. 2008 May;35(5):458-68
pubmed: 18440447
Curr Med Res Opin. 2012 Mar;28(3):457-66
pubmed: 22236136
Pain. 2018 May;159(5):987-994
pubmed: 29419653
J Med Econ. 2013 Dec;16(12):1423-33
pubmed: 24102123
Pain Pract. 2017 Jul;17(6):820-828
pubmed: 27860208
Ann Oncol. 2016 Nov;27(11):2032-2038
pubmed: 27573565
J Clin Oncol. 2017 Jun 10;35(17):1921-1928
pubmed: 28445097
Dig Dis Sci. 2017 Nov;62(11):3156-3166
pubmed: 28986667
J Gastrointestin Liver Dis. 2019 Mar;28(1):41-46
pubmed: 30851171
Pain Ther. 2021 Jun;10(1):165-179
pubmed: 33575953
Pain. 2021 Jan;162(1):309-318
pubmed: 32701649
Expert Rev Clin Pharmacol. 2019 Feb;12(2):121-128
pubmed: 30652502
J Pain Symptom Manage. 2019 May;57(5):899-908.e6
pubmed: 30776537
Neurogastroenterol Motil. 2010 Apr;22(4):424-30, e96
pubmed: 20100280
J Pain Symptom Manage. 2011 Nov;42(5):754-60
pubmed: 22045373
Pain Med. 2009 Jan;10(1):35-42
pubmed: 18721170
Neurosurgery. 2019 Aug 1;85(2):E233-E239
pubmed: 30951602